<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TRAIN" NEWID="6553" OLDID="11466" TOPICS="NO">
<DATE>18-MAR-1987 11:21:06.19</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   F
   f8293 reute
h f BC-LYPHOMED-&lt;LMED&gt;-TO-MA   03-18 0074</UNKNOWN>
<TEXT> 
<TITLE>LYPHOMED &lt;LMED&gt; TO MARKET ANTIBIOTIC</TITLE>
<DATELINE>    ROSEMONT, ILL., March 18 - </DATELINE><BODY>LyphoMed Inc said the Food and
Drug Administration gave it approval to market Vancomycin HCL,
an antibiotic used in hospitals to treat life-threatening
infections.
    It said the product is currently marketed by Eli Lilly and
Co &lt;LLY&gt; under the trade name Vancocin. Sales in 1986 were 110
mln dlrs.
    LyphoMed said its objective is to get a 15 to 20 pct share
of the market.
 Reuter
 </BODY></TEXT>
</REUTERS>